New White Paper: Drug Cost-Sharing Based on Net Price Benefits Medicare Part D Patients

By Stephanie Hedt

Rebates are discounts that lower the price of a product and are used across industries to boost sales. For example, when someone buys a car there are often rebates which reduce the price the consumer pays to well below the sticker price.

Rebates play an important role in the prescription drug market too. But in contrast to car shopping, Medicare patients don’t necessarily benefit from drug rebates when they are at the pharmacy counter. This is because their share of the cost is often based on the list (or pre-rebate) price of drugs. Instead, rebates go to health plans and pharmacy benefit managers. While this helps to reduce premiums, it means that some patients pay more when they fill their prescriptions.

A new Schaeffer Center white paper finds almost half of individuals with Medicare Part D coverage would see a reduction in out-of-pocket spending if patient cost-sharing were based on the price negotiated after the rebate (or net price), rather than the pre-rebate list price.

“Drug rebates have become an increasingly significant component of the Part D program, but our analysis shows beneficiaries are not necessarily benefiting in terms of out-of-pocket spending,” explained Schaeffer Center Associate Director Erin Trish, who co-authored the analysis.

“Although rebates help keep Part D premiums low, they do so in a way that disadvantages those who rely on high cost, high rebate drugs,” says co-author Geoffrey Joyce, Schaeffer Center director of health policy. Joyce and Trish are also faculty at the USC School of Pharmacy.

Savings Range

The study team – which included Trish, Joyce, and Schaeffer Center Research Programmer Katrina Kaiser –used 2016 Medicare Part D claims data to conduct the analysis. To model the policy change basing cost-sharing on net price, rather than list price, they discounted the list price of each claim by the estimated rebate and calculated what the patient’s cost-sharing would have been under this alternative scenario.

The researchers found that basing cost-sharing on net price would reduce out-of-pocket spending for about 47 percent of beneficiaries who do not receive low-income subsidies. For some, the amount would be considerable: approximately 20 percent of beneficiaries would save more than $100 and almost one percent would save more than $1000 annually.

Figure 2: Beneficiary Out-of-Pocket Savings from a Net Price Policy

NOTES: BARS DENOTE THE SHARE OF NON-LIS BENEFICIARIES WHO WOULD FALL INTO EACH CATEGORY OF REDUCTION IN ANNUAL OUT-OF-POCKET SPENDING IF COST-SHARING WAS BASED ON NET PRICE RATHER THAN LIST PRICE. AMONG THE 53.3 PERCENT WITH NO CHANGE IN OUT-OF-POCKET SPENDING, 12 PERCENT OF THEM (ABOUT 6 PERCENT OF ALL NON-LIS BENEFICIARIES) HAVE NO CLAIMS, 52 PERCENT HAVE CLAIMS FOR GENERIC DRUGS ONLY, AND 36 PERCENT HAVE AT LEAST ONE CLAIM FOR A BRANDED DRUG, BUT ALL OF THEIR BRANDED DRUG CLAIMS HAVE ZERO ESTIMATED REBATES. THE MEAN ANNUAL SAVINGS (AMONG BENEFICIARIES WITH NON-ZERO TOTAL SPENDING) IS $91.

Yet the investigators caution that the range of savings can vary widely according to the drugs purchased. Basing cost-sharing on net price would make a significant difference for patients needing high-cost drugs with high rebates, but little difference for patients who take high-cost drugs with low or no rebates. For example, users of the hepatitis C treatment Harvoni would see their out-of-pocket costs for that and other drugs fall by an average of $1,303 a year. However, average spending among users of Ibrance — a drug used for breast cancer — would fall by only $24. This distribution of the policy impact reflects the variation in rebates across different drugs and therapeutic classes.

Figure 3: Mean Total Annual Out-of-Pocket Spending with a List vs. Net Price Policy, Among Patients Taking Drugs with High Out-of-Pocket Spending

NOTES: ANALYSIS INCLUDES USERS OF THE 10 DRUGS WITH THE HIGHEST ANNUAL AVERAGE OUT-OF-POCKET SPENDING PER NON-LIS USER (2016), TAKEN FROM A KAISER FAMILY FOUNDATION ANALYSIS.14 SPENDING INCLUDES TOTAL OUT-OF-POCKET SPENDING ON ALL DRUGS AMONG USERS OF THESE DRUGS. AS NOTED IN THE TEXT, REVLIMID, IMBRUVICA, IBRANCE, ZYTIGA, AND XTANDI ARE PROTECTED CLASS DRUGS.

The study also suggests another important advantage to this net-price shift: it would reduce the number of consumers reaching Part D’s catastrophic coverage phase, during which the federal government pays most of the drug costs. The authors found that 36 percent fewer beneficiaries would reach catastrophic coverage, which would result in a 19 percent reduction in federal reinsurance spending.

The findings show overall savings could be substantial for many patients. The authors note that one concern blocking this reform is that it would likely result in higher premiums. However, the authors also note that that is because some beneficiaries are paying more out-of-pocket, which helps to reduce premiums for everyone. The authors urge federal policymakers to consider implementing this change to how Medicare Part D cost sharing is calculated. Either alone or in conjunction with other reforms, basing rebate amounts on net prices rather than list prices would limit beneficiaries’ out-of-pocket spending and make cost-sharing more reflective of the actual cost of the drug.

Support for this study was provided by the USC Schaeffer Center for Health Policy & Economics.